Selling And Administration Expenses Changement Date
Alnylam Pharmaceuticals USD 198.12M 1.05M 2023-12
BioCryst Pharmaceuticals USD 50.65M 349K 2023-09
Chugai Pharma JPY 27.54B 5.72B 2023-09
Daiichi Sankyo JPY 141.03B 4.45B 2023-09
Enanta Pharmaceuticals USD 13.8M 1.18M 2023-09
Gilead Sciences USD 1.61B 293M 2023-12
GlaxoSmithKline GBP 2.18B 6M 2023-09
Incyte USD 293.86M 25.97M 2023-12
Intra Cellular Therapies USD 104.72M 487K 2023-12
Ionis Pharmaceuticals USD 71.01M 1.06M 2023-12
Neurocrine Biosciences USD 204.2M 17.6M 2023-09
Novavax USD 107.46M 25.24M 2023-09
PTC Therapeutics USD 76.29M 4.6M 2023-12
Regeneron Pharmaceuticals USD 737.7M 97.2M 2023-12
Roche Holding CHF 6.51B 26M 2023-06
Sarepta Therapeutics USD 120.89M 2.33M 2023-09
Ultragenyx Pharmaceutical USD 76.83M 1.92M 2023-12
Vertex Pharmaceuticals USD 263.8M 1.2M 2023-09



BioCryst Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2024.